A
Anthony T Power
Researcher at Max Planck Society
Publications - 10
Citations - 1787
Anthony T Power is an academic researcher from Max Planck Society. The author has contributed to research in topics: Oncolytic virus & Vesicular stomatitis virus. The author has an hindex of 8, co-authored 10 publications receiving 1673 citations. Previous affiliations of Anthony T Power include University of Ottawa.
Papers
More filters
Journal ArticleDOI
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
David F. Stojdl,Brian D. Lichty,Benjamin R. tenOever,Jennifer M Paterson,Anthony T Power,Shane Knowles,Ricardo Marius,Jennifer Reynard,Laurent Poliquin,Harold L. Atkins,Earl G. Brown,Russell K. Durbin,Joan E. Durbin,John Hiscott,John C. Bell +14 more
TL;DR: Evidence is presented that the attenuated vesicular stomatitis strains, AV1 and AV2, embody all of the traits of an oncolytic virus, which will replicate preferentially in malignant cells, have the ability to treat disseminated metastases, and ultimately be cleared by the patient.
Journal ArticleDOI
Vesicular stomatitis virus: re-inventing the bullet
TL;DR: Strains of VSV that induce or direct the production of interferon are superior to wild-type strains of the virus for inducing oncolysis and might also make better vaccine vectors.
Journal ArticleDOI
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.
Anthony T Power,Jiahu Wang,Theresa Falls,Jennifer M Paterson,Kelley Parato,Brian D. Lichty,David F. Stojdl,Peter A. Forsyth,Harry Atkins,John C. Bell +9 more
TL;DR: The severe negative impact of the adaptive immune response on the systemic delivery of oncolytic vesicular stomatitis virus (VSV) in an immune-competent murine tumor model is demonstrated, an effect mediated primarily by the neutralization of injected virions by circulating antibodies.
Journal ArticleDOI
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.
Apollina Goel,Stephanie K. Carlson,Kelly L. Classic,Suzanne Greiner,Shruthi Naik,Anthony T Power,John C. Bell,Stephen J. Russell +7 more
TL;DR: VSV(Delta51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma and is shown to have potential in combination radiovirotherapy with (131)I.
Journal ArticleDOI
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas
Xue Qing Lun,Donna L. Senger,Tommy Alain,Andra Oprea,Kelley Parato,Dave Stojdl,Brian D. Lichty,Anthony T Power,Randal N. Johnston,Mark G. Hamilton,Ian F. Parney,John C. Bell,Peter A. Forsyth +12 more
TL;DR: Systemically delivered VSV(deltaM51) was an effective and safe oncolytic agent against laboratory models of multifocal and invasive malignant gliomas, the most challenging clinical manifestations of this disease.